Equity Overview
Price & Market Data
Price: $0.625
Daily Change: -$0.00115 / 0.18%
Daily Range: $0.60 - $0.625
Market Cap: $7,136,341
Daily Volume: 1,188
Performance Metrics
1 Week: -0.26%
1 Month: 9.91%
3 Months: -60.95%
6 Months: -56.61%
1 Year: -55.37%
YTD: -43.20%
Company Details
Employees: 1
Sector: Health technology
Industry: Biotechnology
Country:
Details
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.